Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation.
Atrial fibrillation
Direct oral anticoagulants
Elderly
Unmet clinical needs
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
20
02
2021
accepted:
30
04
2021
pubmed:
22
5
2021
medline:
23
6
2021
entrez:
21
5
2021
Statut:
ppublish
Résumé
Vitamin K antagonists have been used for many years as the treatment of choice for long-term oral anticoagulation in patients with non-valvular atrial fibrillation. Unfortunately, the use of those drugs in the real-world setting, particularly among elderly patients, is suboptimal because of their limitations in management. Therefore, many patients were not adequately anticoagulated. Direct oral anticoagulants have been demonstrated to overcome almost all the limitations derived from the use of vitamin K antagonists. Direct oral anticoagulants are at least as effective as vitamin K antagonists in preventing thromboembolic events in patients with non-valvular atrial fibrillation and safer in reducing the risk of intracranial haemorrhage and all-cause mortality. However, as a result of the strict inclusion and exclusion criteria applied to patients, data coming from randomized controlled trials might not apply to the general population. Furthermore, elderly patients were scarcely represented in randomized controlled trials with direct oral anticoagulants. Therefore in elderly patients with non-valvular atrial fibrillation, unmet clinical needs still exist. This review article highlights some of them and provides potential answers based on the results coming from randomized clinical trials, real-world data, and the authors' clinical experience.
Identifiants
pubmed: 34019247
doi: 10.1007/s12325-021-01769-9
pii: 10.1007/s12325-021-01769-9
pmc: PMC8189975
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
2891-2907Références
De Caterina R, Camm AJ. What is ‘valvular’ atrial fibrillation? A reappraisal. Eur Heart J. 2014;35:3328–35.
pubmed: 25265975
Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40:235–40.
pubmed: 18757287
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
pubmed: 21870978
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
pubmed: 24251359
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62.
pubmed: 24315724
pmcid: 24315724
Kato ET, Gotob S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev. 2019;49:115–24.
pubmed: 30359765
Dunlay SM, Chamberlain AM. Multimorbidity in older patients with cardiovascular disease. Curr Cardiovasc Risk Rep. 2016;10:3.
pubmed: 27274775
pmcid: 4889124
Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365–75.
pubmed: 31609228
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–95.
pubmed: 16129869
pmcid: 1188185
Patti G, Lucerna M, Pecen L, et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6(7):e005657.
pubmed: 28736385
pmcid: 5586290
Ho P, Brooy BL, Hayes L, Lim WK. Direct oral anticoagulants in frail older adults: a geriatric perspective. Semin Thromb Hemost. 2015;41(4):389–94.
pubmed: 25973587
Ehrlinder H, Orsini N, Modig K, Hofman-Bang C, Wallén H. Gigante B (2020) Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: a cross-sectional analysis of a Swedish single-center clinical cohort. Int J Cardiol Heart Vasc. 2020;27:100505. https://doi.org/10.1016/j.ijcha.2020.100505 .
doi: 10.1016/j.ijcha.2020.100505
pubmed: 32258363
pmcid: 7114891
Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(5):e003432.
pubmed: 27207971
pmcid: 4889207
Nicolau AM, Corbalan R, Nicolau JC, et al. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):167–75.
pubmed: 31687762
Alexander KP, Brouwer MA, Mulder H, et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: insights from the ARISTOTLE trial. Am Heart J. 2019;208:123–31.
pubmed: 30579505
Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016;68(11):1169–78.
pubmed: 27609678
de Groot JR, Weiss TW, Kelly P, et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother. 2021;7:f30–f39. https://doi.org/10.1093/ehjcvp/pvaa079 .
Camm AJ, Fox KAA, Virdone S, et al. Comparative effectiveness of oral anticoagulants in everyday practice. Heart. 2021. https://doi.org/10.1136/heartjnl-2020-318420 .
Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134(1):24–36.
pubmed: 27358434
Wang CC, Kim YH, Brüggenjürgen B, et al. One-year follow-up of elderly patients with atrial fibrillation: data from the global noninterventional programme on edoxaban treatment in routine clinical practice in atrial fibrillation. Presented at the European Society of Cardiology Congress 2019, August 31–September 4, 2019, Paris, France.
Zathar Z, Karunatilleke A, Fawzy AM, Lip GYH. Atrial fibrillation in older people: concepts and controversies. Front Med. 2019;6:175.
Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70(21):2621–32.
Lauw MN, Eikelboom JW, Coppens M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015–23.
pubmed: 28213368
Lee KN, Choi JI, Kim YG, et al. Comparison of renal function estimation formulae for dosing direct oral anticoagulants in patients with atrial fibrillation. J Clin Med. 2019;8(12):2034.
pmcid: 6947455
Hawkins NM, Jhund PS, Pozzi A, et al. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail. 2016;18(9):1162–71.
pubmed: 27594177
Szummer K, Gasparini A, Eliasson S, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc. 2017;6(3):e004925.
pubmed: 28249846
pmcid: 5524023
Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019;74(17):2204–15.
pubmed: 31648714
Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519–29.
pubmed: 29954737
pmcid: 6202193
Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med. 2019;132(9):1078–83.
pubmed: 31054829
Pokorney SD. RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation - RENAL-AF. Presented at the American Heart Association Annual Scientific Sessions 2019.
Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol. 2019;123:2051–7.
pubmed: 30982541
Chao TZ, Liu CJ, Lin YJ, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation. 2018;138:37–47.
pubmed: 29490992
Paciaroni M, Agnelli G, Caso V, et al. Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a risk stratification schema: the ALESSA score study. Stroke. 2017;48:726–32.
pubmed: 28183856
Wilson D, Ambler G, Lee KJ, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol. 2019;18:653–65.
pubmed: 31130428
pmcid: 6562236
Seffige DJ, Paciaroni M, Wilson D, et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol. 2019;85:823–34.
Xian Y, Xu H, O’Brien EC, et al. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke findings from the patient-centered research into outcomes stroke patients refer and effectiveness research (PROSPER) study. JAMA Neurol. 2019;76:1192–202.
pubmed: 31329212
pmcid: 6647003
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.
pubmed: 12466506
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–16.
pubmed: 32865375
Perez A, Touchette DR, DiDomenico RJ, Stamos TD, Walton SM. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis. Pharmacotherapy. 2011;31:552–65.
pubmed: 21923439
Tsadok MA, Jackevicius CA, Essebag V, et al. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 2012;126:2680–7.
pubmed: 23124034
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.
pubmed: 27567408
Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995;129:71–5.
pubmed: 7817928
Gibson CM, Basto AN, Howard ML. Direct oral anticoagulants in cardioversion: a review of current evidence. Ann Pharmacother. 2018;52:277–84.
pubmed: 29025267
Um KJ, Pandey A, et al. Direct oral anticoagulants versus vitamin K antagonists in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2019;33:339–52.
pubmed: 31011880
Telles-Garcia N, Dahal K. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2018;268:143–8.
pubmed: 30041779
Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur J Cardiol. 2014;35:3346–55.
Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomized, open-label, phase 3b trial. Lancet. 2016;388(10055):1995–2003.
pubmed: 27590218
Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39:2959–71.
pubmed: 29659797
pmcid: 6110194
Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. New Engl J Med. 2017;377(16):1513–24.
pubmed: 28844193
Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet. 2013;381(9872):1107–15.
pubmed: 23415013
Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619–29.
pubmed: 25908066
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.
pubmed: 27959713
Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.
pubmed: 30883055
Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomized, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–43.
pubmed: 31492505
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. https://doi.org/10.1093/eurheartj/ehaa575 .
Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective–2018 update. Circulation. 2018;138(5):527–36.
pubmed: 30571525
Lip GYH, Collet J-P, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21(2):192–193.
Capodanno D, Huber K, Mehran R, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI. J Am Coll Cardiol. 2019;74(1):83–99.
pubmed: 31272556
Potpara TS, Mujovic N, Proietti M, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace. 2020;22(1):33–46.
pubmed: 31603196
Galli M, Andreotti F, D’Amario D, et al. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. Eur Heart J Cardiovasc Pharmacother. 2020;6(2):128–9.
pubmed: 31309231
Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40(46):3757–67.
pubmed: 31651946
Haller PM, Sulzgruber P, Kaufmann C, et al. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):226–36.
pubmed: 31198930
Galli M, Andreotti F, Porto I, Crea F. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace. 2020;22(4):538–46.
pubmed: 31942971
Damluji AA, Resar JR, Gerstenblith G, Gross AL, Forman DE, Moscucci M. Temporal trends of percutaneous coronary interventions in older adults with acute myocardial infarction. Circ Cardiovasc Interv. 2019;12(5):e007812.
pubmed: 31010297
pmcid: 6488214
Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320–31.
pubmed: 26417060
pmcid: 4677274
O’Neal WT, Lakoski SG, Qureshi W, et al. Relation between cancer and atrial fibrillation (from the reasons for geographic and racial differences in stroke study). Am J Cardiol. 2015;115(8):1090–4.
pubmed: 25711434
pmcid: 4380860
Raschi E, Diemberger I, Cosmi B, De Ponti F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. Intern Emerg Med. 2018;13(1):1–9.
pubmed: 28942550
D’Souza M, Carlson N, Fosbol E, et al. CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018;25:651–8.
pubmed: 29482441
Fanola CL, Ruff CT, Murphy SA, et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2018;7(16):e008987.
pubmed: 30369307
pmcid: 6201390
Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med. 2017;130(12):1440–8.
pubmed: 28739198
Laube ES, Yu A, Gupta D, et al. Rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation and active cancer. Am J Cardiol. 2017;2:213–7.
Ording AG, Horváth-Puhó E, Adelborg K, Pedersen L, Prandoni P, Sørensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165–72.
pubmed: 28544489
pmcid: 5463075
Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2:200–9.
pubmed: 29378726
pmcid: 5812321
Wolff A, Shantsila E, Lip GY, Lane DA. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing. 2015;44:874–8.
pubmed: 26082176
Atterman A, Friberg F, Asplund K, Engdahl J. Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study. Europace. 2020;22(1):58–65.
pubmed: 31750897
Delluc A, Wang T-F, Yap E-O, et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH Practice Guideline. J Thromb Haemost. 2019;17(8):1247–52.
pubmed: 31207027
Spyropoulos AC, Brohi K, Caprini J, et al. Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural/ surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost. 2019;17:1966–72.
pubmed: 31436045
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.
pubmed: 29562325
Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.
pubmed: 26095867
pmcid: 4931686
Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179(11):1469–78.
pubmed: 31380891
pmcid: 6686768
Colonna P, von Heymann C, Santamaria A, et al. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: the prospective, observational, and multinational EMIT-AF/VTE study. Clin Cardiol. 2020;43(7):769–80.
pubmed: 32406557
pmcid: 7368298
Chang CJ, Hsu LA, Ko YH, et al. Thrombin regulates matrix metalloproteinase-9 expression in human monocytes. Biochem Biophys Res Commun. 2009;385:241–6.
pubmed: 19454280
Gosselin RC, Adcock DM, Bates SM, et al. International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118:437–50.
pubmed: 29433148
Testa S, Tripodi A, Legnani C, et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res. 2016;137:178–83.
pubmed: 26672898
Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–53.
pubmed: 20081065
Vanassche T, Verhamme P, Wells PS, et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018;162:7–14.
pubmed: 29248859
Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868.
Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133:352–60.
pubmed: 26673560
Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55:641–55.
pubmed: 26620048
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.
pubmed: 26324838
Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455–66.
pubmed: 23305158
pmcid: 3769672
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36:164–72.
pubmed: 12085361
LIXIANA. http://www.emaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf . 2018. Accessed 3 July 2015.
Padrini R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur J Drug Metab Pharmacokinet. 2019;44(1):1–12.
pubmed: 30167998
Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs. 2011;71:1503–26.
pubmed: 21861537